Christopher Haqq, EVP, R&D & Chief Scientific Of at Atara Biotherapeutics, Inc. (ATRA), sold 13,500 shares at $43.08 ($582K) on 2018-09-26, disclosed to the SEC on 2018-09-27.
Seasonal sale ($582k) by EVP, R&D & Chief Scientific Of — this insider has traded ATRA in September in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| Filing → |
| ATRA | SELL | 2019-02-08 | $956K | — | Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-25 | $2.0M | — | Filing → |